---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-032763"
form_type: "8-K"
ticker: "INGN"
cik: "0001294133"
company_name: "Inogen Inc"
filed_at: "2023-07-13T23:59:59+00:00"
generated_at: "2026-06-13T08:38:14.334616+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inogen to acquire Physio-Assist for up to $45M; prelim Q2 rev $83-84M

## Summary
- Acquires Physio-Assist for ~$32M cash at closing plus up to $13M on FDA clearance milestones; total capped at $45M.
- Simeox airway clearance device (CE marked) expands product line; US market opportunity estimated at 400k-490k bronchiectasis patients.
- Closing expected Q4 2023 subject to French regulatory approval; Inogen provides up to $500k convertible loan pre-close.
- Preliminary Q2 2023 revenue $83-84M, below expectations; updated 2023 guidance to follow on Aug 7 earnings call.
- Acquisition expected to be accretive to adjusted earnings from 2027 and immediately accretive to gross margin.

## SEC filing metadata
- accession: 0000950170-23-032763
- form_type: 8-K
- ticker: INGN
- cik: 0001294133
- company_name: Inogen Inc
- filed_at: 2023-07-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1294133/000095017023032763/0000950170-23-032763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1294133/000095017023032763/ingn-20230710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-032763
- JSON: https://secwatch.observer/filing/0000950170-23-032763.json
- Plain text: https://secwatch.observer/filing/0000950170-23-032763.txt

## Key facts
- Earnings Releases
  Inogen Inc reported second quarter of 2023 results: revenue in the range of $83 million to $84 million.
  - Period: second quarter of 2023
  - Revenue: in the range of $83 million to $84 million
  - Result: preliminary results
  source text: Inogen estimates preliminary, unaudited total revenue in the second quarter of 2023 to be in the range of $83 million to $84 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1294133/000095017023032763/0000950170-23-032763-index.htm
- Material Agreements
  Inogen Inc entered into Share Purchase Agreement with Mr. Adrien Mithalal, Mr. Jean-Sébastien Lantz, Mrs. Anne Reiser, CAAP Creation, Societe De Capital Risque Provencale Et Corse, Region Sud Investissement, Mérieux Participations 2, Relyens Innovation Santé and certain holders of exercisable securities identified therein valued at approximately $32,000,000 cash at closing (effective 2023-07-10).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Mr. Adrien Mithalal, Mr. Jean-Sébastien Lantz, Mrs. Anne Reiser, CAAP Creation, Societe De Capital Risque Provencale Et Corse, Region Sud Investissement, Mérieux Participations 2, Relyens Innovation Santé and certain holders of exercisable securities identified therein
  - Value: approximately $32,000,000 cash at closing
  - Effective: 2023-07-10
  source text: On July 10, 2023, Inogen, Inc., a Delaware corporation (“Inogen”), entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with Mr. Adrien Mithalal, Mr. Jean-Sébastien Lantz, Mrs. Anne Reiser, CAAP Creation, Societe De Capital Risque Provencale Et Corse, Region Sud Investissement, Mérieux Participations 2, Relyens Innovation Santé and certain holders of exercisable securities identified therein (collectively, the “Sellers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1294133/000095017023032763/0000950170-23-032763-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.